<doi_batch xmlns="http://www.crossref.org/schema/4.4.0" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" version="4.4.0"><head><doi_batch_id>c4f82298-95e5-4053-8804-a110d2aa96fe</doi_batch_id><timestamp>20220310042913607</timestamp><depositor><depositor_name>naun:naun</depositor_name><email_address>mdt@crossref.org</email_address></depositor><registrant>MDT Deposit</registrant></head><body><journal><journal_metadata language="en"><full_title>International Journal of Systems Applications, Engineering &amp; Development</full_title><issn media_type="electronic">2074-1308</issn><archive_locations><archive name="Portico"/></archive_locations><doi_data><doi>10.46300/91015</doi><resource>http://www.naun.org/cms.action?id=3100</resource></doi_data></journal_metadata><journal_issue><publication_date media_type="online"><month>1</month><day>11</day><year>2022</year></publication_date><publication_date media_type="print"><month>1</month><day>11</day><year>2022</year></publication_date><journal_volume><volume>16</volume><doi_data><doi>10.46300/91015.2022.16</doi><resource>https://npublications.com/journals/saed/2022.php</resource></doi_data></journal_volume></journal_issue><journal_article language="en"><titles><title>Lack of an Association Between a Rs9818870 Marker at the Mras Gene Locus and Acute Coronary Syndrome in Czech Males</title></titles><contributors><person_name sequence="first" contributor_role="author"><given_name>Jaroslav A.</given_name><surname>Hubacek</surname><affiliation>Center of Experimental Medicine Institute for Clinical and Experimental Medicine Prague, Czech Republic</affiliation></person_name><person_name sequence="additional" contributor_role="author"><given_name>Jan</given_name><surname>Pitha</surname><affiliation>Center of Experimental Medicine Institute for Clinical and Experimental Medicine Prague, Czech Republic</affiliation></person_name><person_name sequence="additional" contributor_role="author"><given_name>Vera</given_name><surname>Adamkova</surname><affiliation>Department of Preventive Medicine Institute for Clinical and Experimental Medicine Prague, Czech Republic</affiliation></person_name></contributors><jats:abstract xmlns:jats="http://www.ncbi.nlm.nih.gov/JATS1"><jats:p>Acute coronary syndrome (ACS) including myocardial infarction is one of the leading and preventable causes of death in industrialized countries. Conventional cardiovascular risk factors are responsible for approximately 50% of cases. Attention is therefore focused also on genetic variants that are not strongly associated with conventional risk factors. One of them is the rs9818870 marker within the MRAS gene (muscle RAS oncogen homolog-gene, OMIM 608435, 3q22.3), which was recognized as a risk factor for cardiovascular events in Western populations. We analyzed the relationship between the rs9818870 variant and the risk of ACS in the Czech population. Methods: Rs9818870 (C→T) variant was successfully analyzed by PCR-RFLP at the 1,122 control males, younger than 65 years (post- MONICA study) and 1,190 males, consecutive patients with ACS (younger than 65 years). ANOVA and chisquare were used for statistical analyses. Results: Rs9818870 polymorphism was not associated with conventional risk factors (plasma lipids, blood pressure, obesity, smoking, diabetes mellitus) in the control group. We have not detected any association between the DNA marker and ACS (controls – CC = 70.8%, CT = 26.4%, TT = 2.8% vs. patients – CC = 69.7%, CT= 28.2%, TT= 2.1%; P = 0.34). Conclusion: Rs9818870 variant within the MRAS gene region is not robust risk factor for ACS development in the Czech Slavonic males.Acute coronary syndrome (ACS) including myocardial infarction is one of the leading and preventable causes of death in industrialized countries. Conventional cardiovascular risk factors are responsible for approximately 50% of cases. Attention is therefore focused also on genetic variants that are not strongly associated with conventional risk factors. One of them is the rs9818870 marker within the MRAS gene (muscle RAS oncogen homolog-gene, OMIM 608435, 3q22.3), which was recognized as a risk factor for cardiovascular events in Western populations. We analyzed the relationship between the rs9818870 variant and the risk of ACS in the Czech population. Methods: Rs9818870 (C→T) variant was successfully analyzed by PCR-RFLP at the 1,122 control males, younger than 65 years (post- MONICA study) and 1,190 males, consecutive patients with ACS (younger than 65 years). ANOVA and chisquare were used for statistical analyses. Results: Rs9818870 polymorphism was not associated with conventional risk factors (plasma lipids, blood pressure, obesity, smoking, diabetes mellitus) in the control group. We have not detected any association between the DNA marker and ACS (controls – CC = 70.8%, CT = 26.4%, TT = 2.8% vs. patients – CC = 69.7%, CT= 28.2%, TT= 2.1%; P = 0.34). Conclusion: Rs9818870 variant within the MRAS gene region is not robust risk factor for ACS development in the Czech Slavonic males.</jats:p></jats:abstract><publication_date media_type="online"><month>3</month><day>10</day><year>2022</year></publication_date><publication_date media_type="print"><month>3</month><day>10</day><year>2022</year></publication_date><pages><first_page>41</first_page><last_page>43</last_page></pages><publisher_item><item_number item_number_type="article_number">8</item_number></publisher_item><ai:program xmlns:ai="http://www.crossref.org/AccessIndicators.xsd" name="AccessIndicators"><ai:free_to_read start_date="2022-03-10"/><ai:license_ref applies_to="am" start_date="2022-03-10">https://npublications.com/journals/saed/2022/a162014-008(2022).pdf</ai:license_ref></ai:program><archive_locations><archive name="Portico"/></archive_locations><doi_data><doi>10.46300/91015.2022.16.8</doi><resource>https://npublications.com/journals/saed/2022/a162014-008(2022).pdf</resource></doi_data><citation_list><citation key="ref0"><unstructured_citation>J.A. Hubacek, V. Stanek, M. Gebauerova, A. Pilipcincova, D. Dlouha, R. Poledne, et al. „A FTO variant and risk of acute coronary syndrome,“ Clin. Chim. Acta. vol. 411, pp. 1069-1072, 2010. </unstructured_citation></citation><citation key="ref1"><unstructured_citation>J.A. Hubacek, V. Staněk, M. Gebauerová, R. Poledne, M. Aschermann, H. Skalicka, et al. „Association between a marker on chromosome 9 and acute coronary syndrome. Confirmatory study on Czech population,“ Folia Biol. (Praha), vol. 58, pp. 203-208, 2012. </unstructured_citation></citation><citation key="ref2"><unstructured_citation>J. Erdmann, A. Grosshennig, P.S. Braund, I.R. Konig, C. Hengstenberg, A.S. Hall, et al. „New susceptibility locus for coronary artery disease on chromosome 3q22.3,“ Nat. Genet. vol. 41, pp. 280- 282, 2009. </unstructured_citation></citation><citation key="ref3"><unstructured_citation>C.J. O'Donnell, M. Kavousi, A.V. Smith, S.L. Kardia, M.F. Feitosa, S.J. Hwang, et al. „Genome-wide association study for coronary artery calcification with follow-up in myocardial infarction.“. Circulation, vol. 124, pp. 2855-2864, 2011. </unstructured_citation></citation><citation key="ref4"><doi>10.1161/circgenetics.111.960336</doi><unstructured_citation>K.L. Ellis, C.M. Frampton, A.P. Pilbrow, R.W. Troughton, R.N. Doughty, G.A. Whaley, et al. „Genomic risk variants at 1p13.3, 1q41, and 3q22.3 are associated with subsequent cardiovascular outcomes in healthy controls and in established coronary artery disease,“. Circ. Cardiovasc. Genet. vol. 4, pp. 636-646, 2011. </unstructured_citation></citation><citation key="ref5"><unstructured_citation>J.A. Hubacek, V. Staněk, M. Gebauerová, A. Pilipcincova, R. Poledne, M. Aschermann et al. „Lack of an association between connexin-37, stromelysin-1, plasminogen activator-inhibitor type 1 and lymphotoxinalpha genes and acute coronary syndrome in Czech Caucasians,“ Exp. Clin. Cardiol. vol. 15, pp. e52-e56, 2010. </unstructured_citation></citation><citation key="ref6"><unstructured_citation>H. Tunstall-Pedoe, K. Kuulasmaa, H. Tolonen, M. Davidson and S. Mendis. MONICA monograph and multimedia sourcebook. (2003). Tunstal-Pedoe H, editor. Geneva: World Health Organization</unstructured_citation></citation></citation_list></journal_article></journal></body></doi_batch>